Downregulation of long non‑coding RNA LINC‑PINT serves as a diagnostic and prognostic biomarker in patients with non‑small cell lung cancer

Zhang,Chunjie; Gong,Cuixue; Li,Jianzhao; Tang,Jiaying

doi:10.3892/ol.2021.12471

Downregulation of long non‑coding RNA LINC‑PINT serves as a diagnostic and prognostic biomarker in patients with non‑small cell lung cancer

Authors:
- Chunjie Zhang
- Cuixue Gong
- Jianzhao Li
- Jiaying Tang
View Affiliations

Affiliations: Department of Clinical Laboratory, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China, Outpatient Dressing Room, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China, Department of Pathology, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China, Department of Blood Transfusion, Zibo Central Hospital, Zibo, Shandong 255036, P.R. China
Published online on: January 18, 2021 https://doi.org/10.3892/ol.2021.12471
Article Number: 210
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) play an important role in gene regulation. Several lncRNAs have been demonstrated to be associated with the diagnosis and prognosis of non‑small cell lung cancer (NSCLC). The present study aimed to investigate the role of lncRNA long intragenic non‑protein‑coding RNA p53‑induced transcript (LINC‑PINT) in NSCLC to identify a novel non‑invasive biomarker for the diagnosis and prognosis of patients with NSCLC. Reverse transcription‑quantitative PCR analysis was performed to detect LINC‑PINT expression in the tissue and serum samples of patients with NSCLC. The diagnostic and prognostic values of LINC‑PINT were assessed via the receiver operating characteristic curve, and Kaplan‑Meier and Cox regression analyses, respectively. The results demonstrated that LINC‑PINT expression was significantly downregulated in NSCLC serum samples and tissues. In addition, serum LINC‑PINT exhibited diagnostic value in patients with NSCLC, and may be used to predict prognosis. Furthermore, aberrant LINC‑PINT expression in tumor tissues was significantly associated with lymph node metastasis, tumor size, differentiation and TNM stage. Taken together, the results of the present study suggest that lncRNA LINC‑PINT may be an independent diagnostic and prognostic biomarker in NSCLC.

View Figures

View References

1	Nanavaty P, Alvarez MS and Alberts WM: Lung cancer screening: Advantages, controversies, and applications. Cancer Control. 21:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
3	Cheung CHY and Juan HF: Quantitative proteomics in lung cancer. J Biomed Sci. 24:372017. View Article : Google Scholar : PubMed/NCBI
4	de Sousa VML and Carvalho L: Heterogeneity in lung cancer. Pathobiology. 85:96–107. 2018. View Article : Google Scholar : PubMed/NCBI
5	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
6	Syrigos KN, Saif MW, Karapanagiotou EM, Oikonomopoulos G and De Marinis F: The need for third-line treatment in non-small cell lung cancer: An overview of new options. Anticancer Res. 31:649–659. 2011.PubMed/NCBI
7	Richard PJ and Rengan R: Oligometastatic non-small-cell lung cancer: Current treatment strategies. Lung Cancer (Auckl). 7:129–140. 2016.PubMed/NCBI
8	Hirsch FR, Suda K, Wiens J and Bunn PA Jr: New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X and Ta S: LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 485:229–233. 2018. View Article : Google Scholar : PubMed/NCBI
10	Peng WX, Koirala P and Mo YY: LncRNA-Mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
11	Bhan A, Soleimani M and Mandal SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981. 2017. View Article : Google Scholar : PubMed/NCBI
12	Feng H, Zhang J, Shi Y, Wang L, Zhang C and Wu L: Long noncoding RNA LINC-PINT is inhibited in gastric cancer and predicts poor survival. J Cell Biochem. 120:9594–9600. 2019. View Article : Google Scholar : PubMed/NCBI
13	Duan J, Ma X, Shi J, Xuan Y, Wang H, Li P, Zhang Y, Fan Y, Gong H, Ma X, et al: Long noncoding RNA LINC-PINT promotes proliferation through EZH2 and predicts poor prognosis in clear cell renal cell carcinoma. Onco Targets Ther. 12:4729–4740. 2019. View Article : Google Scholar : PubMed/NCBI
14	Hong L, Wang H, Wang J, Wei S, Zhang F, Han J, Liu Y, Ma M, Liu C, Xu Y and Jiang D: LncRNA PTCSC3 inhibits tumor growth and cancer cell stemness in gastric cancer by interacting with lncRNA linc-pint. Cancer Manag Res. 11:10393–10399. 2019. View Article : Google Scholar : PubMed/NCBI
15	Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, Liu H, Xu J, Xiao F, Zhou H, et al: A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 9:44752018. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Hu J, Li J, Yang Q, Hao M and Bu L: Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4. Artif Cells Nanomed Biotechnol. 47:1595–1602. 2019. View Article : Google Scholar : PubMed/NCBI
17	Wang S, Jiang W, Zhang X, Lu Z, Geng Q, Wang W, Li N and Cai X: LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN. Cancer Med. 9:1999–2009. 2020. View Article : Google Scholar : PubMed/NCBI
18	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Chassagnon G, Bennani S and Revel MP: New TNM classification of non-small cell lung cancer. Rev Pneumol Clin. 73:34–39. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
21	Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: Diagnosis and management. Am Fam Physician. 75:56–63. 2007.PubMed/NCBI
22	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al: Non-Small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 15:504–535. 2017. View Article : Google Scholar
23	Gong HY, Wang Y, Han G and Song QB: Radiotherapy for oligometastatic tumor improved the prognosis of patients with non-small cell lung cancer (NSCLC). Thorac Cancer. 10:1136–1140. 2019. View Article : Google Scholar : PubMed/NCBI
24	Jonna S and Subramaniam DS: Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): An update. Discov Med. 27:167–170. 2019.PubMed/NCBI
25	Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J: MiR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 8:e603172013. View Article : Google Scholar : PubMed/NCBI
26	Camidge DR, Doebele RC and Kerr KM: Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 16:341–355. 2019. View Article : Google Scholar : PubMed/NCBI
27	Gao P, Wang H, Yu J, Zhang J, Yang Z, Liu M, Niu Y, Wei X, Wang W, Li H, et al: MiR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2. PLoS Genet. 14:e10077902018. View Article : Google Scholar : PubMed/NCBI
28	Wang SY, Li Y, Jiang YS and Li RZ: Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:4092–4097. 2017.PubMed/NCBI
29	Zhang G, Wang Q, Zhang X, Ding Z and Liu R: LncRNA FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2 axis. Biomed Pharmacother. 118:1093092019. View Article : Google Scholar : PubMed/NCBI
30	He R, Zhang FH and Shen N: LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC). Biomed Pharmacother. 95:331–338. 2017. View Article : Google Scholar : PubMed/NCBI
31	Yang T, Li H, Chen T, Ren H, Shi P and Chen M: LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis. Mol Cells. 42:270–283. 2019.PubMed/NCBI
32	Liu W: LncRNA LINC-PINT inhibits cancer cell proliferation, invasion, and migration in osteosarcoma by downregulating miRNA-21. Cancer Biother Radiopharm. 34:258–263. 2019. View Article : Google Scholar : PubMed/NCBI
33	Chao Y and Zhou D: lncRNA-D16366 is a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma. Med Sci Monit. 25:6581–6586. 2019. View Article : Google Scholar : PubMed/NCBI
34	Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z, Tian H, He J, Shen W, Tian H, et al: Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta. 486:26–33. 2018. View Article : Google Scholar : PubMed/NCBI
35	Xie Y, Zhang Y, Du L, Jiang X, Yan S, Duan W, Li J, Zhan Y, Wang L, Zhang S, et al: Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol. 12:648–658. 2018. View Article : Google Scholar : PubMed/NCBI
36	Huang SH and O'Sullivan B: Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
37	Saffarzadeh AG, Blasberg JD and Beyond TNM: Searching for new patient-centric prognostic indicators in NSCLC. Ann Surg Oncol. 25:3425–3426. 2018. View Article : Google Scholar : PubMed/NCBI
38	Zhou M, Zhang Z, Zhao H, Bao S, Cheng L and Sun J: An immune-related six-lncRNA signature to improve prognosis prediction of glioblastoma multiforme. Mol Neurobiol. 55:3684–3697. 2018.PubMed/NCBI